Clinical trial
Combination Chemotherapy in Treating Patients With Relapsed or Refractory…
NCT00053105 · Theradex, Industry · Unknown status
Key facts
| NCT number | NCT00053105 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma |
| Official title | A Phase I Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin in the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma |
| Lead sponsor | Theradex, Industry |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | cisplatin, cytarabine, methylprednisolone, pixantrone dimaleate |
| Start date | Feb 1, 2002 |
| First posted | Jan 28, 2003 |
| Last update posted | Jul 7, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: